NYSEAMERICAN:AMPE

Ampio Pharmaceuticals (AMPE) Stock Forecast, Price & News

$0.31

+0.02 (+6.93%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.29
▼
$0.31
50-Day Range: $0.20
▼
$0.30
52-Week Range: $0.18
▼
$3.94

Volume: 117,906 shs
Average Volume: 288,406 shs
Market Capitalization: $4.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Ampio Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$33,298 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ampio Pharmaceuticals.

2.0

Short Interest

Percentage of Shares Shorted
5.38% of the float of Ampio Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ampio Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Ampio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ampio Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMPE.

3.0

News and Social Media Coverage

News Sentiment
Ampio Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ampio Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Ampio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ampio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,298.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.88% of the stock of Ampio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 19.82% of the stock of Ampio Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Ampio Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ampio Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ampio Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Stock News Headlines

May 26, 2023 | finance.yahoo.com

Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock

May 15, 2023 | americanbankingnews.com

Insider Buying: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Purchases $11,000.00 in Stock

May 31, 2023 | UNKNOWN (Ad)

This NASDAQ Stock Is The Amazon Of Medical Supply

This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now

May 6, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSE:AMPE)

April 28, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.com

April 22, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com

April 18, 2023 | seekingalpha.com

Ampio stock jumps ~20% after CEO letter on drug program, reorganization

April 14, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com

May 31, 2023 | UNKNOWN (Ad)

This NASDAQ Stock Is The Amazon Of Medical Supply

This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now

April 14, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by Analysts at StockNews.com

April 14, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by StockNews.com

April 13, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Earns Sell Rating from Analysts at StockNews.com

April 12, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated by Analysts at StockNews.com

April 11, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)

April 9, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated at StockNews.com

April 6, 2023 | americanbankingnews.com

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Receives New Coverage from Analysts at StockNews.com

April 4, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)

April 3, 2023 | thestreet.com

Ampio Too Busy to Tell Investors Results of Eye Drug Study

February 9, 2023 | thestreet.com

Why Ampio Pharmaceuticals (AMPE) Stock Is Plummeting Today

February 7, 2023 | wsj.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.

December 27, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

November 17, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

November 8, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split

October 16, 2022 | stockhouse.com

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

October 16, 2022 | prnewswire.com

AMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPE

October 12, 2022 | benzinga.com

MONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

October 7, 2022 | prnewswire.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Company Calendar

Last Earnings: 5/08/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSEAMERICAN:AMPE
Previous Symbol: NYSE:AMPE
CUSIP: 03209T10
CIK: 1411906
Web: ampiopharma.com
Phone: (720) 437-6500
Fax: 720-437-6501
Employees: 20
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.8493)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.46%
Return on Assets: -69.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.67
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.02 per share
Price / Book: 0.15

Miscellaneous

Outstanding Shares: 15,093,000
Free Float: 14,960,000
Market Cap: $4.66 million
Optionable: Optionable
Beta: 1.48

Key Executives

Michael A. Martino
Chief Executive Officer & Director

Daniel G. Stokely
Chief Financial Officer & Secretary

Howard Levy
Chief Medical Officer

Lane Hapke
Vice President-Manufacturing Operations

Laura Goldberg
Vice President-Quality & Regulatory Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMPE Stock - Frequently Asked Questions

How have AMPE shares performed in 2023?: Ampio Pharmaceuticals' stock was trading at $0.2252 at the start of the year. Since then, AMPE stock has increased by 37.0% and is now trading at $0.3085.
View the best growth stocks for 2023 here.
When is Ampio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our AMPE earnings forecast.
How were Ampio Pharmaceuticals' earnings last quarter?: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) announced its quarterly earnings results on Monday, May, 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter.
What other stocks do shareholders of Ampio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Rigel Pharmaceuticals (RIGL), Cogent Biosciences (UMRX), ADMA Biologics (ADMA), Great Panther Mining (GPL), Zosano Pharma (ZSAN) and Miragen Therapeutics (MGEN).

What is Ampio Pharmaceuticals' stock symbol?: Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."
Who are Ampio Pharmaceuticals' major shareholders?: Ampio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include HRT Financial LP (1.44%). Insiders that own company stock include Dan Stokely, David R Stevens, Holli Cherevka, Michael A Martino and Philip H Coelho.
View institutional ownership trends.
How do I buy shares of Ampio Pharmaceuticals?: Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ampio Pharmaceuticals' stock price today?: One share of AMPE stock can currently be purchased for approximately $0.31.
How much money does Ampio Pharmaceuticals make?: Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) has a market capitalization of $4.66 million. The specialty pharmaceutical company earns $-17,080,000.00 in net income (profit) each year or ($1.8493) on an earnings per share basis.
How can I contact Ampio Pharmaceuticals?: Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The official website for the company is ampiopharma.com. The specialty pharmaceutical company can be reached via phone at (720) 437-6500, via email at info@ampiopharma.com, or via fax at 720-437-6501.

This page (NYSEAMERICAN:AMPE) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ampio Pharmaceuticals (AMPE) Stock Forecast, Price & News

Ampio Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

AMPE Stock News Headlines

AMPE Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMPE Stock - Frequently Asked Questions

Overall MarketRank^™